Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

Paolo Nuciforo, John Townend,Martine J. Piccart, Shona Fielding, Panagiota Gkolfi,Sarra El-Abed,Evandro de Azambuja,Gustavo Werutsky,Judith Bliss,Volker Moebus,Marco Colleoni,Alvaro Moreno Aspitia,Henry Gomez,Andrea Gombos,Maria A. Coccia-Portugal,Ling-Ming Tseng,Georg Kunz, Guillermo Lerzo,Joohyuk Sohn,Vladimir Semiglazov,Cristina Saura,Judith Kroep,Antonella Ferro,David Cameron,Richard Gelber,Jens Huober,Serena Di Cosimo

European Journal of Cancer（2023）

引用 1|浏览75

暂无评分

摘要

•Neoadjuvant lapatinib and/or trastuzumab treatment optimisation is the longest-lasting neoadjuvant study in human epidermal growth factor receptor-2 (HER2)-positive breast cancer.•Patients with pathological complete response (pCR) show better survival than those without pCR.•This gain is especially seen in hormone-receptor-negative or dual anti-HER2 subgroups.•pCR benefit is durable as hazard risk is low (er) even after 5–10 years from surgery.

查看译文

关键词

Breast cancer,HER2-Positive,Neoadjuvant,Pathological complete response,Long-term survival,Dual anti-HER2 blockade

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要